Human GFAP (Glial Fibrillary Acidic Protein) ELISA Kit
The Human GFAP (Glial Fibrillary Acidic Protein) ELISA Kit is expertly designed to quantitatively detect levels of GFAP in a variety of human biological samples. GFAP, a vital protein predominantly found in astrocytes, serves as a marker for astrocytic activation and is instrumental in maintaining central nervous system integrity. Its quantification plays a crucial role in understanding neuroinflammatory processes, neural injury, and diseases involving astrocyte dysfunction.
Our GFAP ELISA Kit ensures exceptional sensitivity and specificity, guaranteeing accurate and reproducible results. With stringent manufacturing processes and quality control measures, this kit offers robust performance and user-friendly procedures, making it an excellent choice for both research and clinical purposes. Rely on our GFAP ELISA Kit for precise and reliable quantification of this significant biomarker in your scientific endeavors.
Product Name:
Human GFAP (Glial Fibrillary Acidic Protein) ELISA Kit
SKU:
AEES00127
Target:
Human GFAP (Glial Fibrillary Acidic Protein)
Size:
96T
Assay type:
Sandwich-ELISA
Assay time:
3.5h
Sensitivity:
9.38 pg/mL
Detection range:
15.63-1000 pg/mL
Kit component:
Component
Quantity (24 Assays)
Quantity (96 Assays)
Storage
Micro ELISA Plate (Dismountable)
8 wells x 3 strips
8 wells x 12 strips
-20°C, 12 months
Reference Standard
1 vial
2 vials
Concentrated Biotinylated Detection Ab (100×)
1 vial, 60 µL
1 vial, 120 µL
Concentrated HRP Conjugate (100×)
1 vial, 60 µL
1 vial, 120 µL
-20°C (shading light), 12 months
Reference Standard & Sample Diluent
1 vial, 20 mL
1 vial, 20 mL
4°C, 12 months
Biotinylated Detection Ab Diluent
1 vial, 14 mL
1 vial, 14 mL
HRP Conjugate Diluent
1 vial, 14 mL
1 vial, 14 mL
Concentrated Wash Buffer (25×)
1 vial, 30 mL
1 vial, 30 mL
Substrate Reagent
1 vial, 10 mL
1 vial, 10 mL
4°C (shading light)
Stop Solution
1 vial, 10 mL
1 vial, 10 mL
4°C
Plate Sealer
5 pieces
5 pieces
Product Description
1 copy
1 copy
This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human GFAP. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human GFAP and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human GFAP, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human GFAP. You can calculate the concentration of Human GFAP in the samples by comparing the OD of the samples to the standard curve.
Linearity:
Serum (n=5)
EDTA plasma (n=5)
Cell culture media (n=5)
1:2
Range (%)
95-103
88-98
97-109
Average (%)
100
93
105
1:4
Range (%)
83-95
92-103
95-107
Average (%)
90
98
101
1:8
Range (%)
84-98
93-103
96-107
Average (%)
91
99
99
1:16
Range (%)
95-105
87-96
99-107
Average (%)
100
91
104
Recovery:
Sample Type
Range (%)
Average Recovery (%)
Serum (n=5)
88-96
91
EDTA plasma (n=5)
93-104
99
Cell culture media (n=5)
101-107
104
Precision:
Intra-assay Precision
Inter-assay Precision
Sample
1
2
3
1
2
3
n
20
20.0
20.0
20.0
20.0
20.0
Mean (ng/mL)
41.27
118.65
432.44
44.06
112.01
408.43
Standard deviation
2.46
5.54
19.98
2.41
5.35
22.26
C V (%)
5.96
4.67
4.62
5.47
4.78
5.45
Sample type &Sample volume:
serum, plasma and other biological fluids; 100μL
Reproducibility:
Both intra-CV and inter-CV are < 10%.
Application:
This ELISA kit applies to the in vitro quantitative determination of Human GFAP concentrations in serum, plasma and other biological fluids.
Specificity:
This kit recognizes Human GFAP in samples. No significant cross-reactivity or interference between Human GFAP and analogues was observed.
